Min Fangfang, Hu Jielun, Huang Tao, Huang Yousheng, Nie Shaoping, Xiong Tao, Xie Mingyong
State Key Laboratory of Food Science and Technology, China-Canada Joint Lab of Food Science and Technology (Nanchang), Key Laboratory of Bioactive Polysaccharides of Jiangxi Province, Nanchang University, 235 Nanjing East Road, Nanchang, 330047, China; Institute of Development and Research, Jiangxi General Institute of Testing and Certification, 171 Beijing East Road, Nanchang, 330029, China.
State Key Laboratory of Food Science and Technology, China-Canada Joint Lab of Food Science and Technology (Nanchang), Key Laboratory of Bioactive Polysaccharides of Jiangxi Province, Nanchang University, 235 Nanjing East Road, Nanchang, 330047, China.
Food Chem Toxicol. 2023 Apr;174:113662. doi: 10.1016/j.fct.2023.113662. Epub 2023 Feb 11.
Lactobacillus (L.) casei NCU011054 isolated from infant feces has been proven to be a potential probiotic in vitro. The present study aimed to investigate the effects of L. casei NCU011054 on the immune response and gut microbiota in cyclophosphamide (CP)-induced immunosuppression mice. Results indicated that L. casei NCU011054 could increase the levels of mucin (Muc2) and tight junction proteins (ZO-1, occludin and claudin-1). Moreover, L. casei NCU011054 was found to upregulate TLRs/NF-κB pathway (TLR-2, TLR-4, TLR-6, p65 and NF-κB) and two transcription factors (T-bet and GATA-3) mRNA levels, and enhance the number of CD4T cells. Th1-related cytokines (IL-12p70, IFN-γ and TNF-α) and Th2-related cytokines (IL-2, IL-4, IL-6 and IL-10) significantly increased after L. casei NCU011054 treatment. More importantly, L. casei NCU011054 increased the ratio of T-bet to GATA-3 and IFN-γ to IL-4. Apart from these, L. casei NCU011054 remodeled gut microbiota and modulated gut metabolites in CP-induced immunosuppressed mice. The correlation analysis showed that Lactobacillus upregulated by L. casei NCU011054 was positively correlated with TLRs/NF-κB pathway, and the ratio of T-bet to GATA-3 and IFN-γ to IL-4. All findings revealed that L. casei NCU011054 could improve intestinal immune dysfunction and modulate Th1/Th2 balance via TLRs/NF-κB pathway in CP-induced immunosuppressed mice.
从婴儿粪便中分离出的干酪乳杆菌（L.）NCU011054已被证明在体外是一种潜在的益生菌。本研究旨在探讨干酪乳杆菌NCU011054对环磷酰胺（CP）诱导的免疫抑制小鼠免疫反应和肠道微生物群的影响。结果表明，干酪乳杆菌NCU011054可增加粘蛋白（Muc2）和紧密连接蛋白（ZO-1、闭合蛋白和claudin-1）的水平。此外，发现干酪乳杆菌NCU011054上调TLRs/NF-κB通路（TLR-2、TLR-4、TLR-6、p65和NF-κB）以及两种转录因子（T-bet和GATA-3）的mRNA水平，并增加CD4T细胞数量。干酪乳杆菌NCU011054处理后，Th1相关细胞因子（IL-12p70、IFN-γ和TNF-α）和Th2相关细胞因子（IL-2、IL-4、IL-6和IL-10）显著增加。更重要的是，干酪乳杆菌NCU011054增加了T-bet与GATA-3以及IFN-γ与IL-4的比例。除此之外，干酪乳杆菌NCU011054重塑了CP诱导的免疫抑制小鼠的肠道微生物群并调节了肠道代谢产物。相关性分析表明，干酪乳杆菌NCU011054上调的乳酸杆菌与TLRs/NF-κB通路以及T-bet与GATA-3和IFN-γ与IL-4的比例呈正相关。所有研究结果表明，干酪乳杆菌NCU011054可改善CP诱导的免疫抑制小鼠的肠道免疫功能障碍并通过TLRs/NF-κB通路调节Th1/Th2平衡。
